A second phase Ib clinical trial in patients with paroxysmal nocturnal hemoglobinuria (PNH) to assess the safety, preliminary efficacy and pharmacokinetics of subcutaneously administered APL-2 alone or in combination with eculizumab

Trial Profile

A second phase Ib clinical trial in patients with paroxysmal nocturnal hemoglobinuria (PNH) to assess the safety, preliminary efficacy and pharmacokinetics of subcutaneously administered APL-2 alone or in combination with eculizumab

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs APL 2 (Primary) ; Eculizumab
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Mar 2018 According to an Apellis media release, updates from this study are anticipated in the first half of 2018.
    • 21 Nov 2016 Data from this and another phase Ib trial will be presented at the International PNH Interest Group (IPIG) Annual Scientific Assembly 2016, according to an Apellis Pharmaceuticals media release.
    • 28 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top